Cargando…
Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC
Pazopanib is a potent multi-targeted kinase inhibitor approved for the treatment of advanced renal cell carcinoma and soft tissue sarcoma. The pharmacokinetics of pazopanib is characterized by a significant inter- and intra-patient variability and a target through plasma concentration of 20.5 mg·L(−...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469080/ https://www.ncbi.nlm.nih.gov/pubmed/34577627 http://dx.doi.org/10.3390/ph14090927 |